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Lipoprotein(a) (Lp(a)) is a complex serum lipoprotein consist-
ing of a low-density lipoprotein core associated by a disulfide
bond with apolipoprotein(a), a heterogenous glycoprotein
that, due to its structural homology with plasminogen, com-
petes for fibrin binding, inhibits tissue plasminogen activator,
and ultimately impairs fibrinolysis.1,2 It has been recognized
that more than 90% of variation of plasma Lp(a) concentration
is genetically regulated, with apolipoprotein(a) gene (LPA)
being a major determinant. To date, several genetic variants
in the LPA gene have been shown to influence Lp(a) plasma
values, rs3798220 and rs10455872 polymorphisms account-
ing in particular for at least 40% of such variation.3 Because of
its dual nature (i.e., proatherosclerotic low-density lipopro-
tein-like andprothrombotic plasminogen-like), Lp(a) has been
thesubjectof intense researchover thepast 20years fromboth
in vivo and in vitro studies that have analyzed its
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Abstract Elevated plasma levels of lipoprotein(a) (Lp(a)) are associated with increased cardio-
vascular risk in several clinical studies. However, there is a lack of data supporting a
positive association between elevated Lp(a) levels and venous thromboembolism
(VTE). Thus, we conducted a systematic review of the literature to better clarify its role
as a risk factor for VTE. Medline and the Embase (up to May 2015) electronic databases
were used to identify potentially eligible studies. Studies measuring Lp(a) values in
adult patients with deep vein thrombosis and/or pulmonary embolism and in a
population of patients without a VTE were selected. Studies on patients with major
venous thromboembolic events occurring at other unusual site, case reports, and case
series were excluded. The odds ratios (ORs) of the association between high values of
Lp(a) and VTE and the weighted mean difference (WMD) in Lp(a) levels in cases and in
controls were calculated using a random-effect model. Results were presented with
95% confidence interval (CI). Fourteen studies for a total of more than 14,000 patients
were finally included in our analysis. Lp(a) was slightly but significantly associated with
an increased risk of VTE (OR: 1.56, 95% CI: 1.36, 1.79; 10 studies, 13,541 patients). VTE
patients had significantly higher Lp(a) values compared with controls (WMD: 14.46
mg/L, 95% CI: 12.14, 16.78; 4 studies, 470 patients). Lp(a) appeared to be significantly
associated with increased risk of VTE. However, Lp(a) levels were only slightly increased
in VTE patients compared with controls.
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prothrombotic properties.4–6 Elevated plasma levels of Lp(a)
were found to be associated with an increased cardiovascular
risk in several retrospective and prospective clinical studies.1
Notably, a meta-analysis of almost 5,500 patients with coro-
nary artery disease prospectively followedup for an average of
10 years reported that individuals with Lp(a) values in the top
tertile had an approximately 70% increased risk of coronary
arterydiseaseevents comparedwith individualswithvalues in
the bottom tertile.7 Although convincing epidemiological evi-
dences were brought forward to propose a causal role of Lp(a)
in the development, progression, and complication of occlu-
sive arterial disease, data supporting a positive association
between elevated Lp(a) values and venous thromboembolism
(VTE) are less consistent. A previous systematic review and
meta-analysis of the literature conducted a decade ago and
including a limited number of studies found a statistically
significant, albeit modest, association between high Lp(a)
(>300 mg/L) and VTE (odds ratio [OR]: 1.87, 95% confidence
interval [CI]: 1.51–2.30).8 On the other hand, a more recent
study reported an association between two variants of the LPA
gene (rs10455872 and rs3798220 polymorphisms) and sys-
temic and coronary atherosclerosis, but not with VTE.9 There-
fore, tobetter clarify the role of Lp(a) as a risk factor forVTE,we
conducted an extensive systematic review of the literature
updating the results of the previous meta-analysis.
Methods
A protocol for this review was prospectively developed,
detailing specific objectives, criteria for study selection, ap-
proach to assess study quality, outcomes, and statistical
methods.
Search Strategy
Using the Medline and the Embase (up to May 2015) elec-
tronic databases without any language restriction, we iden-
tified all published studies that evaluated the role of Lp(a) as
a potential risk factor for VTE. We supplemented our search
by manually reviewing abstract books from the Congress of
the International Society on Thrombosis and Haemostasis
(ISTH) (2011–2015), and the reference lists of all retrieved
articles, manually searching recent issues of thrombosis and
hemostasis journals. Search results were reported according
to Meta-analysis Of Observational Studies in Epidemiology
(MOOSE) reporting guidelines.10
Study Selection
Two reviewers (V.G. andM.G.) performed the study selection
independently, with disagreements solved through discus-
sion and by the opinion of a third reviewer (F.D.) if necessary.
Studies were considered potentially eligible for this system-
atic review if theymet the following criteria: they included a
population of patientswith deep vein thrombosis (DVT) and/
or pulmonary embolism (PE) and a population of patients
without a VTE (controls); Lp(a) values were measured in
both patients with VTE and controls. Patients with major
venous thromboembolic events at other unusual sites (e.g.,
splanchnic vein thrombosis and cerebral vein thrombosis)
were not included in our systematic review. Furthermore,
studies that only included patientswith VTE recurrencewere
excluded. Finally, we did not include case reports, case series,
and studies on patients younger than 18 years.
Data Extraction
Two reviewers (V.G. and M.G.) independently extracted data
on study (year of publication, design) and population charac-
teristics (number of patients, mean age, sex). Information on
Lp(a) levels in VTE patients and in controls was also collected.
Statistical Analysis and Risk of Bias Assessment
Statistical analysis was performed using Review Manager
(Version 5.2) provided by The Cochrane Collaboration
(Copenhagen, Denmark). The ORs of the association between
highvalues of Lp(a) andVTE and theweightedmeandifference
of Lp(a) values in case and in controls were calculated using a
random-effect model.11 The overall effect was tested using
Z-scores, and significance was set at p < 0.05. Results were
presentedwith 95% CI. Statistical heterogeneity was evaluated
using the I2 statistic and the chi-square Cochrane Q test, which
assess the appropriateness of pooling the individual study
results.12 Heterogeneity was considered significant when
p < 0.10.Wealsoestimated theproportionofVTE in thepopu-
lation that could be attributed to elevated Lp(a) (population-
attributable risk [PAR]) with the following formula:
PAR ¼ 100  [Prevalence (OR-1)/Prevalence (OR-1) þ 1]
For this calculation, we estimated the prevalence of expo-
sure as frequency of elevated values of Lp(a) (> 300 mg/dL)
among control subjects. Publication bias was graphically
represented by funnel plots of the effect size versus the
standard error.
Results
A total of 262 (90 Medline, 172 Embase) citations were
identified by our systematic search (►Fig. 1). A total of 216
studies were excluded after title and abstract screening
based on the predefined inclusion and exclusion criteria or
because they were duplicates. Of the 32 studies retrieved in
full text for more in-depth evaluation, 18 were excluded
because they did not have a control group without VTE, did
not provide information about the number of subjects with
Lp(a) values above a pre-specified cut-off, they included
children, or they considered patients with VTE other than
DVT or PE (e.g., retinal vein occlusion). The interobserver for
the study selection was perfect. Thus, 14 studies for a total
number of 2,824 cases of VTE and 11,187 controls were
included in our systematic review.13–26 Baseline character-
istics of the included studies are summarized in ►Table 1.
Only one study provided separate data of patients with
unprovoked VTE22 and two studies also included patients
with two or more episodes of VTE (15.5% in the study by
Vormittag et al and 23% in the study by Marcucci et al).18,22
Association between Lp(a) value and the risk of VTE was
evaluated in 10 studies13–22 for a total of 2,607 VTE patients
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and 10,934 controls. Lp(a) cut-off used for the analysis was
the upper limit of the manufacturer’s product reference
range (usually 300 mg/L) in nine studies13–16,18–22 and the
75th percentile of Lp(a) value in the control group in one
study. 14 Lp(a) was significantly associatedwith an increased
risk of VTE (OR: 1.56, 95% CI: 1.36, 1.79; ►Fig. 2). The
estimated attributable risk of VTE conferred by elevated
levels of Lp(a) was 19.8%. Heterogeneity among studies
was significant (I2: 77%, chi-square: 39.67; p < 0.001).
Exclusion from the analysis of the study performed by
Kamstrup et al significantly lowered the heterogeneity
among the studies (I2: 56%; p ¼ 0.02).16
The funnel plots of effect size versus standard error
appeared symmetrical, suggesting the absence of publica-
tion bias (►Fig. 3).
Meanvalue of Lp(a) in cases and in controlswas compared
in four studies23–26 for a total of 470 patients (217 VTE
patients and 253 controls). VTE patients had significantly
higher Lp(a) levels compared with controls (WMD: 14.46
mg/L, 95% CI: 12.14, 16.78; ►Fig. 4). Heterogeneity among
the studies was significant (I2: 95%, chi-square: 62.44;
p < 0.001). Exclusion from the analysis of the study per-
formed by Ogunyemi et al significantly lowered the hetero-
geneity (I2: 75%, p ¼ 0.02).25
Discussion
Many observations have pointed out that Lp(a) levels may be
a risk factor for arterial cardiovascular and cerebrovascular
diseases, by inhibiting the activation of transforming growth
factor and contributing to the growth of arterial atheroscle-
rotic lesions by promoting proliferation of vascular smooth
muscle cells and migration of smooth muscle cells to endo-
thelial cells.27 Furthermore, Lp(a) may act as a proinflam-
matory mediator, increasing the lesion formation in
atherosclerotic plaques.27 Due to structural homology with
plasminogen, this lipoprotein may also compete with plas-
minogen for its receptors on endothelial cells, thus leading to
diminished plasmin formation, thereby delaying clot lysis
and favoring venous thrombosis.28 However, evidence on its
role as a risk factor for venous thromboembolic events
remains controversial.29
Our meta-analysis, including data from 14 case–control
studies for a total of 2,824 VTE patients and 11,187 healthy
controls, showed a significant but only slight association
between Lp(a) levels and VTE. The risk attributable to the
presence of high levels of Lp(a) appeared globally modest
(19.8%) and theWMD in Lp (a) values in cases and in controls
was only 14.46 mg/L, a value that is likely composed of the
analytical variability of the commercial immunoassays used
for measuring Lp(a).30
In previous meta-analysis performed by Sofi et al,8 the
presence of high Lp(a) values was significantly associated
with increased riskof VTE. However, their results were based
on six studies for a total of 1,786 VTE patients and 1,024
controls only, and they did not calculate the risk of VTE
attributable to the presence of high Lp(a) values, nor did they
evaluate theWMD of this parameter in cases and in controls.
In a previous large prospective study performed by Tsai
et al, high values of Lp(a) were not found to be significantly
associated with increased risk of developing VTE.31,32 The
LITE study included 19,921 participants with no VTE history
Fig. 1 Results of the systematic search.
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at baseline, were not taking warfarin, and had Lp(a)
measured. The age and sex-adjusted hazard ratio for
Lp(a) >300 mg/L versus 300 mg/L was 1.12 (95% CI:
0.55–2.27) for whites and 1.31 (95% CI: 0.69–2.47) for blacks,
thus suggesting that the association between elevated Lp(a)
and VTE was likely modest, if any.
Furthermore, Lp(a) appeared to have a limited role in
identifying patients at high risk of VTE recurrence. In a quite
large prospective study, elevated Lp(a) levels do not appear
to be associated with recurrent VTE in patients with history
of unprovoked VTE,33 and no study has demonstrated that Lp
(a)-lowering therapy might be beneficial in reducing the
incidence of VTE recurrence, at least in some subgroups of
patients with high Lp(a) levels.
Therefore, the results of our meta-analysis confirm the
questionable role of Lp(a) as a risk factor for VTE. Overall, Lp
(a) appeared aweak risk factor for venous thrombosis, so that
its extensive evaluation outside the context of clinical
research in patients with a previous VTE does not appear
justified, also considering that the current methods available
on the market are quite expensive.
Our meta-analysis has several potential limitations. First,
the application of formal meta-analytic methods to observa-
tional studies is controversial, because inherent bias in the
study design may misrepresent the strength of associations
within data.10 To minimize this potential bias, we included
only studies inwhich the diagnosis of venous thromboembolic
event was objectively confirmed. Second, studies included
in our meta-analysis have different inclusion and exclusion
criteria, and to combine results across studies may be inap-
propriate. Furthermore, the heterogeneity among the studies
was significant, suggesting caution in the interpretation of the
results. Different study design and difference in the popula-
tion evaluated (e.g., pregnant patients) may explain heteroge-
neity among the studies. Another important drawback is the
use of different methods for measuring Lp(a), each of which
displays different performance due to the heterogeneity of the
molecule being measured. Due to the lack of universal stan-
dard and reference antibodies, the size effects of larger or
different isoforms may lead to conflicting conclusions when
pooling data.34 However, we decided to combine our results
using the random-effect model, an approach that takes into
account the variance among the studies. Third, due to the
limits of a study-level meta-analysis, we were not able to
Fig. 2 Forrest plot evaluating the association between elevated levels of Lp(a) and the risk of VTE. CI, confidence interval.
Fig. 3 Funnel plots of effect size versus standard error evaluating the
presence of publication bias.
Fig. 4 Forrest plot evaluating the weighted mean difference in Lp(a) levels in VTE cases and in controls. CI, confidence interval.
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adjust our results for these potential risk factors; therefore, we
could not analyze the association with specific subgroup of
patients (e.g., patientswithunprovokedVTE). Finally, although
an extensive research of the literature was performed and
the funnel plots of effect size versus standard error
appeared symmetrical, the presence of publication bias, albeit
extremely unlikely, could not be definitively excluded.
In conclusion, Lp(a) appeared to be significantly associ-
ated with increased risk of VTE. However, Lp(a) levels were
only slightly increased in VTE patients compared with
controls and the heterogeneity of the analytical techniques
is still a cause for large bias. Thus, an extensive evaluation
of this parameter in all the patients with a previous VTE
does not appear justified. Other prospective studies evalu-
ating the role of Lp(a)-specific subgroups of patients with
VTE (e.g., patients with an unprovoked event) are still
warranted.
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